Royalty Pharma Financing Growth Alternative Traditional Biopharmaceutical Fundraising
Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insights/royalty-financing-alternative-traditional-biopharma-fundraising
Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insights/royalty-financing-alternative-traditional-biopharma-fundraising
Royalty Pharma Financing Growth Alternative Traditional Biopharmaceutical Fundraising
Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insights/royalty-financing-alternative-traditional-biopharma-fundraising
0 Kommentare
0 Geteilt
95 Ansichten
0 Bewertungen
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
